or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    EXEL B 2.24 6.67
    RVMD C -0.05 5.90
    GILD C 0.48 5.81
    BGNE D -2.08 5.16
    INCY C 1.89 4.99
    ACLX C 3.69 4.09
    SRPT D 3.38 3.75
    MRK F -0.68 3.20
    REGN F -0.87 3.11
    SWTX C 7.49 2.80
    TWST D 1.37 2.72
    LGND B 2.27 2.40
    GERN D 1.24 2.36
    IOVA F 3.76 2.16
    BEAM D 6.23 2.12
    DVAX C 0.49 1.88
    BCRX D 1.47 1.74
    BPMC C -2.56 1.55
    NRIX D -1.43 1.49
    NVAX F 5.35 1.26
    MRNA F 7.48 1.06
    CRSP D 3.43 0.98
    IBRX C 1.29 0.91
    RCUS F 2.94 0.80
    VIR D 2.45 0.72
    ARCT F -0.94 0.49
    OABI F 1.82 0.43
    FDMT F -2.50 0.41
    XNCR B 3.78 0.38
    NTLA F 3.62 0.34
    QURE D -1.11 0.33
    DNA F 8.95 0.27
    EDIT F 2.95 0.23
    MGNX F 0.93 0.22

    Represented by ETF Holdings

    Keywords: Biotechnology Biopharmaceutical Cancer Medicine Biology Life Sciences Immune System Infectious Diseases Monoclonal Antibodies Antibodies Clinical Development Clinical Medicine Coronavirus Genetics Immunology Influenza S&P 500 Cancer Treatment Enzymes Nasdaq 100
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research

    Recent News for iShares Genomics Immunology and Healthcare ETF & its Holdings

    Date Stock Title
    Nov 23 INCY What Moved Markets This Week
    Nov 23 MRK Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC
    Nov 22 MRK Merck recommends rejection of TRC Capital’s 'mini-tender' offer
    Nov 22 MRK Merck Recommends Rejection of TRC Capital’s "Mini-Tender" Offer
    Nov 22 MRNA Jefferies says market nears short term “peak RFK negativity", Vaccine makers up
    Nov 22 MRNA Goldman Sachs: Moderna, Inc. (NASDAQ:MRNA) Is A Top Growth Investor Stock
    Nov 22 XNCR Xencor: Plamotamab NHL Data Leads To RA Program Advancement
    Nov 22 MRNA Moderna Stock Jumps Following Bullish Sales View at Healthcare Conference
    Nov 22 SRPT High Growth Tech Stocks to Watch in November 2024
    Nov 22 MRNA Moderna up 8% as Jefferies says market is close to 'peak RFK negativity'
    Nov 22 MRNA Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
    Nov 22 MRK Merck-marketed asthma drug linked to psychiatric issues: report
    Nov 22 MRK Merck gets Chinese approval for Welireg for VHL tumors
    Nov 22 IOVA 2 Innovative Stocks That Could Deliver Outsize Returns
    Nov 22 MRK Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
    Nov 22 NTLA Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
    Nov 22 IOVA Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
    Nov 22 MRK Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
    Nov 22 GERN Geron Corp. (GERN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
    Nov 22 MRK Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
    The investment seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma Index. The fund generally will invest at least 90% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 10% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
    Exchange Traded Fund Immunology Genomics
    Back to the Main IDNA Page...